145 related articles for article (PubMed ID: 36787553)
1. Waldenstrom Macroglobulinemia Arising During Maintenance Therapy of Plasma Cell Myeloma.
Jin N; Ye P; Chen C; Xiao D
Clin Lab; 2023 Feb; 69(2):. PubMed ID: 36787553
[TBL] [Abstract][Full Text] [Related]
2. Does Waldenstrom's macroglobulinemia also cause bone destruction? A rare case report.
Lin JM; Yuan XJ; Zhang L; Li G; Gan XR; Xu WH
J Int Med Res; 2022 Apr; 50(4):3000605221096161. PubMed ID: 35485877
[TBL] [Abstract][Full Text] [Related]
3. Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual.
Wang E; Kulbacki E; Stoecker M
Hum Pathol; 2012 Jul; 43(7):1135-41. PubMed ID: 22404949
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Carulli G; Ciancia EM; Azzarà A; Ottaviano V; Grassi S; Ciabatti E; Ferreri MI; Rocco M; Marini A; Petrini M
J Clin Exp Hematop; 2013; 53(1):29-36. PubMed ID: 23801131
[TBL] [Abstract][Full Text] [Related]
5. IgM myeloma and Waldenstrom's macroglobulinemia: a distinct clinical feature, histology, immunophenotype, and chromosomal abnormality.
Chehal A; Taher A; Shamseddine A
Clin Lab Haematol; 2003 Jun; 25(3):187-90. PubMed ID: 12755797
[TBL] [Abstract][Full Text] [Related]
6. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Ghobrial IM; Siegel DS; Vij R; Berdeja JG; Richardson PG; Neuwirth R; Patel CG; Zohren F; Wolf JL
Am J Hematol; 2016 Jun; 91(4):400-5. PubMed ID: 26800393
[TBL] [Abstract][Full Text] [Related]
7. Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
Bladé J; Montoto S; Rosiñol L; Montserrat E
Semin Oncol; 2003 Apr; 30(2):329-31. PubMed ID: 12720163
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia.
Chaudhry M; Steiner R; Claussen C; Patel K; Lee H; Weber D; Thomas S; Feng C; Amini B; Orlowski R; Feng L; Manasanch EE
Leuk Lymphoma; 2019 Apr; 60(4):964-970. PubMed ID: 30227761
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
[TBL] [Abstract][Full Text] [Related]
10. Skeletal clues apparently distinguishing Waldenstrom's macroglobulinemia from multiple myeloma and leukemia.
Rothschild BM; Ruhli F; Rothschild C
Am J Hum Biol; 2002; 14(4):532-7. PubMed ID: 12112574
[TBL] [Abstract][Full Text] [Related]
11. Unusual evolution of Waldenström's macroglobulinemia into osteolytic myeloma.
Jondeau K; Alterescu R; Franc B; Davi F; Massé JM; Boukour S; Le Parc JM; Cramer EM
Eur J Haematol; 2006 Jul; 77(1):74-9. PubMed ID: 16827885
[TBL] [Abstract][Full Text] [Related]
12. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.
Schuster SR; Rajkumar SV; Dispenzieri A; Morice W; Aspitia AM; Ansell S; Kyle R; Mikhael J
Am J Hematol; 2010 Nov; 85(11):853-5. PubMed ID: 20842638
[TBL] [Abstract][Full Text] [Related]
13. [Persistent paraproteinemia in the absence of myeloma or Waldenstrom's disease].
Despont JP; Fluckiger R; Gahith A; Hausser E; Jeannet M; Monnier J; Scheidegger JJ; Siegenthaler P; Wettstein P; Cruchaud A
Helv Med Acta Suppl; 1967 May; 47():136-7. PubMed ID: 4999867
[No Abstract] [Full Text] [Related]
14. IgM multiple myeloma: report of four cases and review of the literature.
Annibali O; Petrucci MT; Del Bianco P; Gallucci C; Levi A; Foà R; Avvisati G
Leuk Lymphoma; 2006 Aug; 47(8):1565-9. PubMed ID: 16966268
[TBL] [Abstract][Full Text] [Related]
15. Myeloma and macroglobulinemia: what are the criteria for diagnosis?
Stone MJ
Clin Lymphoma; 2002 Jun; 3(1):23-5. PubMed ID: 12141951
[TBL] [Abstract][Full Text] [Related]
16. 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia.
Avet-Loiseau H; Garand R; Lodé L; Robillard N; Bataille R
Semin Oncol; 2003 Apr; 30(2):153-5. PubMed ID: 12720126
[TBL] [Abstract][Full Text] [Related]
17. A case of anaplastic large cell (Ki-1) lymphoma of B-cell phenotype, occurring in Waldenström's macroglobulinemia.
Hamada T; Ishizuka H; Asai Y; Yamazaki T; Sawada U; Hasegawa H; Uchida T
Pathol Int; 1999 Oct; 49(10):913-7. PubMed ID: 10571827
[TBL] [Abstract][Full Text] [Related]
18. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM).
Kobayashi Y
Int J Hematol; 2019 Nov; 110(5):524-528. PubMed ID: 31494831
[No Abstract] [Full Text] [Related]
19. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T
PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040
[TBL] [Abstract][Full Text] [Related]
20. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.
Paiva B; Montes MC; García-Sanz R; Ocio EM; Alonso J; de Las Heras N; Escalante F; Cuello R; de Coca AG; Galende J; Hernández J; Sierra M; Martin A; Pardal E; Bárez A; Alonso J; Suarez L; González-López TJ; Perez JJ; Orfao A; Vidríales MB; San Miguel JF
Leukemia; 2014 Jan; 28(1):166-73. PubMed ID: 23604227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
